LENZ Therapeutics Soars 17.33% on FDA Approval, Strategic Partnership

LENZ Therapeutics' stock surged 17.33% in pre-market trading on August 11, 2025, marking a significant rise in investor interest and confidence in the company's prospects.

LENZ Therapeutics recently secured a strategic partnership with Laboratoires Théa, granting Théa exclusive rights to develop, manufacture, register, and commercialize LNZ100 for presbyopia treatment in Canada. This collaboration is expected to bolster LENZ Therapeutics' market presence and revenue streams, contributing to the positive market sentiment.

Additionally, the U.S. FDA's approval of LENZ Therapeutics' Vizz (aceclidine ophthalmic solution) for presbyopia treatment has further solidified the company's position in the ophthalmic market. Vizz is the first aceclidine-based eye drop approved for adults, offering a novel treatment option for presbyopia patients.